Keeler Thomas Management LLC Has $268,000 Stake in Kenvue Inc. $KVUE

Keeler Thomas Management LLC reduced its position in Kenvue Inc. (NYSE:KVUE) by 87.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,812 shares of the company’s stock after selling 91,481 shares during the quarter. Keeler Thomas Management LLC’s holdings in Kenvue were worth $268,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of KVUE. Pittenger & Anderson Inc. bought a new position in Kenvue in the 1st quarter valued at about $30,000. Trust Co. of Vermont increased its holdings in Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after buying an additional 1,150 shares during the period. TruNorth Capital Management LLC bought a new position in Kenvue in the 1st quarter valued at about $36,000. Truvestments Capital LLC bought a new position in Kenvue in the 1st quarter valued at about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd increased its holdings in Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after buying an additional 1,287 shares during the period. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Zacks Research raised shares of Kenvue to a “strong sell” rating in a report on Monday, August 11th. Redburn Partners set a $22.00 price target on shares of Kenvue in a report on Friday, September 26th. The Goldman Sachs Group decreased their price target on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. Finally, Bank of America decreased their price target on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $20.75.

Kenvue Stock Down 0.6%

NYSE:KVUE opened at $15.00 on Friday. The firm’s 50 day simple moving average is $17.91 and its 200 day simple moving average is $20.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. Kenvue Inc. has a one year low of $14.05 and a one year high of $25.17. The company has a market cap of $28.78 billion, a PE ratio of 20.26, a P/E/G ratio of 2.17 and a beta of 0.72.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. The business had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm’s revenue was down 4.0% compared to the same quarter last year. During the same period last year, the company earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a $0.2075 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.5%. Kenvue’s dividend payout ratio is presently 112.16%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.